Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.78 |
| ▸ | MEN1 | O00255 | 8/20 | 0.78 |
| ▸ | NPC1 | O15118 | 7/20 | 0.78 |
| ▸ | RAB9A | P51151 | 7/20 | 0.78 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982130 | 0.92 | KMT2A (0.67) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL2815751 | 0.92 | KMT2A (0.74) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL14311488 | 0.89 | RAB9A (0.76) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL2299556 | 0.89 | KMT2A (0.67) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL13598030 | 0.89 | KMT2A (0.67) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL13597992 | 0.88 | SERPINE1 (0.69) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL14311489 | 0.86 | RAB9A (1.00) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL13598036 | 0.86 | KMT2A (0.78) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL13597991 | 0.86 | KMT2A (0.67) | KMT2AMEN1NPC1RAB9AEGFR | |
| SCHEMBL13598024 | 0.85 | KMT2A (0.73) | KMT2AMEN1NPC1RAB9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202982-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-QUINOLINE-3-CARBOXAMIDE POTASSIUM SALT FOR TREATING INFLAMMATORY BOWEL DISEASES | AQILION AB (SE) | 2023-06-29 | — | — | US | disclosed |
| US-20230167064-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | AQILION AB (SE) | 2023-06-01 | — | — | US | disclosed |
| CN-115916200-A | Treatment of inflammatory bowel disease | 阿奎利恩有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4142724-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | Aqilion AB (SE) | 2023-03-08 | — | — | EP | disclosed |
| US-20220031628-A1 | NANOPARTICLES FOR PREPARING REGULATORY B CELLS | UNIVERSITÉ PARIS CITÉ (FR) | 2022-02-03 | — | — | US | disclosed |
| WO-2021219879-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | AQILION AB (SE) | 2021-11-04 | — | — | WO | disclosed |
| US-20210220481-A1 | BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES | UNIVERSITÉ PARIS CITÉ (FR) | 2021-07-22 | — | — | US | disclosed |
| EP-3829557-A1 | BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020025408-A1 | BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2020-02-06 | — | — | WO | disclosed |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | disclosed |
| EP-2627638-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. | Immunahr AB (SE) | 2013-08-21 | — | — | EP | disclosed |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | IMMUNAHR AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | IMMUNAHR AB (SE) | 2013-08-08 | — | — | US | disclosed |
| CN-103153959-A | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators | IMMUNAHR AB | 2013-06-12 | — | — | CN | disclosed |
| CN-103153959-A | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators | IMMUNAHR AB | 2013-06-12 | — | — | CN | disclosed |
| CN-103153959-A | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators | IMMUNAHR AB | 2013-06-12 | — | — | CN | disclosed |
| WO-2012050500-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. | PETTERSSON LARS (SE) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012050500-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. | PETTERSSON LARS (SE) | 2012-04-19 | — | — | WO | disclosed |
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-12-31 | — | — | US | disclosed |
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | KMT2A 4780/4885MEN1 2345/4885NPC1 163/4885 |
| US-20210220481-A1 | BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES | IAPP, AHR, ARNT | KMT2A 3166/4885MEN1 2413/4885NPC1 1415/4885 |
| US-20220031628-A1 | NANOPARTICLES FOR PREPARING REGULATORY B CELLS | IAPP, IL2, CCR10 | KMT2A 2962/4885MEN1 2738/4885NPC1 1843/4885 |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, NFATC1, CD4 | KMT2A 3866/4885MEN1 4304/4885NPC1 1204/4885 |
| US-20230167064-A1 | TREATMENTS OF INFLAMMATORY BOWEL DISEASE | SLC10A2, SI, ALPI | KMT2A 3547/4885MEN1 2883/4885NPC1 504/4885 |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | AHR, HRH4, ARNT | KMT2A 761/4885MEN1 3486/4885NPC1 3628/4885 |
| US-20230202982-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-QUINOLINE-3-CARBOXAMIDE POTASSIUM SALT FOR TREATING INFLAMMATORY BOWEL DISEASES | SLC10A2, KCNK5, KCNQ5 | KMT2A 88/4885MEN1 2958/4885NPC1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.